CELLinCELLS

Notifications

Pipeline	Status	R&D Plan		Potential Indications
TRTP-101	Phase 1 Completed (Atrophic Scar)	- Continued development of atrophic scar therapy - Expansion of indications for dermal-related unmet needs - Expansion of indications in other areas using and improving data such as *CMC(chemistry, manufacturing and control) of TRTP-101		- Atrophic scar - Wounds - Burn - Wrinkle - Decubitus ulcer - Hair loss
		TRTP-102	Injectable osteoarthritis therapy (regenerative medicine)	Osteoarthritis, meniscus damage
		TRTP-103	Ligament and Tendon regenerative medicine	Frozen shoulder
		TRTP-104	Plastic surgery	Hair loss
TRTP-20X	Pre-clinical	Severe cartilage defects / osteoarthritis organoid regenerative medicine		- Severe cartilage defects - Osteoarthritis
TRTP-30X	MoA, CMC	- Pure human organoid-derived extracellular matrix - Exosome		Medical materials (materials such as medical devices and cosmetics)
TRTP-40X	MoA, CMC	Angiogenetic organoid product		- Buerger's disease - Diabetic ulcer / diabetes mellitus wound
TRTP-50X	MoA, CMC	Organoid technology-based muscle therapy		- Sarcopenia - Charcot-Marie-Tooth
TRTP-90X	Cell Bank Technology	- Stem cell / organoid cell bank technology - Cryopreservation technology

Pipeline	Status	R&D Plan		Potential Indications
TRTP-101	Phase 2 (Atrophic Scar)	- Continued development for atrophic scar treatment - Expansion into indications addressing unmet needs in dermatology		- Atrophic scars - Burns - Acne scars - Hair loss
		TRTP-102	Injectable Osteoarthritis Therapy	Osteoarthritis, Partial-thickness cartilage defects
		TRTP-103	Ligament & Tendon Regeneration	Rotator cuff tears
		TRTP-104	Skin Lightening & Hair Follicle Regeneration	Hair loss, Alopecia
TRTP-201	Pre-clinical	- Organoid-based cartilage regeneration therapy - Confirmation of efficacy in large animal models		Cartilage defects / Osteoarthritis(*DMOAD)
TRTP-30X	Process Development	Development of pure human-derived organoid-based *ECM therapeutic materials		Medical materials(Medical devices, Medical cosmetics, etc.)
TRTP-40X	Research / MOA	- Development of vascularized organoid - based regenerative therapies		- Cardiovascular diseases - Diabetes
TRTP-90X	Allogeneic Cell Banking	- Stem cell/organoid cell differentiation technology - Cryopreservation technology - AI–stem cell/organoid convergence technology		- Stem cell/organoid regenerative therapies - High-quality commercialization - Global development / commercialization